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Abstract
Background: Clozapine is an effective treatment for a proportion of people with schizophrenia (SZ) who are resistant to
the beneficial effects of other antipsychotic drugs. However, anything from 40–60 % of people on clozapine experience
residual symptoms even on adequate doses of the medication, and thus could be considered ‘clozapine resistant’. Agents
that could work alongside clozapine to improve efficacy whilst not increasing the adverse effect burden are both desired
and necessary to improve the lives of individuals with clozapine-resistant SZ. N-Acetylcysteine (NAC) is one such possible
agent. Previous research from our research group provided promising pilot data suggesting the efficacy of NAC in this
patient population. The aim of the study reported here is to expand this work by conducting a large scale clinical trial of
NAC in the treatment of clozapine-resistant SZ.
Methods: This study is an investigator initiated, multi-site, randomised, placebo-controlled trial. It aims to include 168
patients with clozapine-resistant SZ, divided into an intervention group (NAC) and a control group (placebo). Participants
in the intervention group will receive 2 g daily of NAC. The primary outcome measures will be the negative symptom
scores of the Positive and Negative Syndrome Scale (PANSS). Secondary outcome measures will include: changes in
quality of life (QoL) as measured by the Lancashire Quality of Life Profile (LQoLP) and cognitive functioning as measured
by the total score on the MATRICS. Additionally we will examine peripheral and cortical glutathione (GSH) concentrations
as process outcomes.
Discussion: This large scale clinical trial will investigate the efficacy of NAC as an adjunctive medication to clozapine.
This trial, if successful, will establish a cheap, safe and easy-to-use agent (NAC) as a ‘go to’ adjunct in patients that are only
partly responsive to clozapine.
Trial registration: Australian and New Zealand Clinical Trials Registration Number: Current Randomised Controlled Trial
ACTRN12615001273572. The date of registration 23 November 2015.
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Schizophrenia (SZ) is a severe and enduring mental
illness, afflicting 1 % of the population. Despite some
treatment advances, most notably the discovery of the
antipsychotic drugs, many people with SZ continue to
suffer substantial disability associated with ongoing
distressing symptoms. For example, in Australia (where
this trial will take place) the recent Survey of High
Impact Psychosis (SHIP) found that 41.3 % of the 1825
participants with a psychotic illness were, despite treatment,
experiencing persistent psychotic symptoms [1]. Negative
symptoms and cognitive deficits are the most poorly
responsive to pharmacological interventions, yet carry the
greatest disability in terms of poorer overall personal, social
and occupational functioning.
Clozapine
Clozapine is the most effective antipsychotic drug for
treatment–resistant SZ. Due to the significant adverse
event profile, it is generally only prescribed to those who
have not responded to other antipsychotics and is often
considered a ‘last resort’. Clozapine is recommended in all
major treatment algorithms for treatment resistant SZ. It
is commonly prescribed in Australia, with 22 % of the
SHIP sample being on this agent. However, a substantial
proportion of people with SZ do not respond adequately
to clozapine, with 40–60 % having residual negative and
cognitive symptoms despite an adequate trial of clozapine
[2] or due intolerable side effects which limit the option of
increasing clozapine dose. Attempts to enhance the thera-
peutic efficacy of clozapine have met with mixed success.
A recent review by the Castle (Chief Investigator of this
study) outlined a range of augmentation strategies that
have been investigated in people who ‘failed’ clozapine.
These include other antipsychotics, antidepressants, mood
stabilisers, and glutamatergic agents, and although some
showed benefits for a proportion of patients, strategies
that have been encouraging in small case series have
mostly not been confirmed in subsequent more rigorous
studies [3]. Agents that could work alongside clozapine to
improve efficacy whilst not increasing the side effect
burden are essential if we are to improve to lives of
clozapine-resistant SZ patients. One such potential agent
is N-acetylcysteine (NAC), a glutathione (GSH) precursor.
N-Acetylcysteine (NAC)
NAC has been shown to modulate a number of processes
involved in psychiatric disorders including neuroinflam-
mation, oxidative stress, and the regulation of glutamate
and dopamine neurotransmitter systems. NAC has been
trialled as an augmenting agent for a range of disorders
including addiction (smoking, cocaine, cannabis and
gambling for example), autism, Alzheimer’s, attention
deficit hyperactivity disorder (ADHD), and impulse con-
trol disorders (nail biting, skin picking, trichotillomania)
to name a few [4]. While more high quality trials are
needed to confirm the efficacy of NAC in these disorders,
at this stage the results are promising.
The study described here is born out of a previous rando-
mised controlled trial of NAC as an adjunctive therapy for
SZ specifically [5]. Investigators for this previous trial
assessed the efficacy of NAC as an adjunct to treatment as
usual in people with SZ; of the 140 enrolled participants,
45 % were on clozapine. Overall, results showed significant
improvements on the Clinical Global Impression-Severity
Scale (CGI-S; d = 0.43; p < 0.05) and Positive and Negative
Syndrome Scale (PANSS), negative (d = 0.52; p < 0.05) and
general (d = 0.46; p < 0.05) subscales. NAC was extremely
well tolerated with no significant adverse events reported in
the NAC group. Additionally, abnormal involuntary move-
ments (a side effect of antipsychotic medication) were
reduced during NAC treatment. Secondary analyses using
the clozapine patients only [6], showed these benefits were
robust for the clozapine patient group. That is, there were
significant reductions in PANSS negative scores from base-
line to endpoint in the NAC group. Adjusting for baseline
score using least square means, the difference between the
placebo (n = 24) and NAC (n = 25) groups was statistically
significant (Mdiff = 3.87, SE = 1.84, 95 % CI [0.14, 7.59], p <
0.05, d = 0.61). Importantly, Farokhnia et al. [7], in an inde-
pendent study, also demonstrated similar improvements for
NAC for negative symptoms of SZ (as an adjunct to risperi-
done). Given these findings, and the lack of studies to date
that have specifically targeted those prescribed clozapine,
the current trial is timely and warranted. Furthermore, the
pilot work clearly indicates the feasibility of the trial design.
Quality of life
A review of the literature shows that people diagnosed
with SZ report a lower quality of life (QoL) than the
general population [8, 9]. Contributing factors include
psychotic symptoms [10], as well as depression and
anxiety [11]. Neurocognition has also been linked to
QoL with greater cognitive functioning linked to higher
objective but lower subjective QoL [12]. Finally, insight
has actually been shown to reduce subjective QoL [13].
Cognition
Cognitive impairment is common in SZ and is thought
to play a role in non-response to drug treatment. Indeed,
a recent study by de Bartolomeis et al. [14] established
that people with treatment resistant SZ had significantly
poorer verbal memory and executive function than
responders. Additionally, severity of global cognitive
impairment was significantly correlated with negative
symptom severity in this treatment resistant cohort.
There is now substantial evidence from animal studies
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that NAC improves cognitive function [15], more specif-
ically attention, executive function and memory. There
has been very little investigation of the impact of NAC
on cognition in human studies. Some early evidence
indicates that it may improve specific areas of cognition
including memory [16]. Besides being associated with
treatment response, cognitive impairment is also associ-
ated with poorer social and occupational outcome [17].
Research suggests that improvements in cognition
(through cognitive remediation for example) are associated
with improvements in these areas [18]. Thus, in the pro-
posed study, we will investigate neurocognitive changes as
a secondary outcome measure. We will include premorbid
IQ, current IQ and general cognition as examined using
the MATRICS, which is considered the gold-standard cog-
nitive assessment in clinical trials for patients with SZ [19].
Biological mechanisms
Our study has also been designed to enable a novel in-
vestigation of the biological effects of NAC treatment.
This includes the measurement of peripheral markers
including thiols (such as GSH, cysteine, cysteinyl-
glycine, NAC) and corresponding disulphides (such as
glutathione disulphide (GSSG) and cystine). These ana-
lyses will be used to track longitudinal changes in GSH
and related compounds through the course of the
proposed trial. In addition to peripheral GSH, we will
measure cortical GSH via proton magnetic spectroscopy
(MRS). Recently there have been substantial develop-
ments in both the field strength and spectral acquisition
of MRS which now permits the accurate measurement
of GSH in the human brain in vivo. For example, Do et
al. [20] demonstrated that GSH is reduced in the cortex
of SZ patients using MRS. Therefore, we will use in vivo
MRS to assess changes in cortical GSH levels in a subset
of participants in the proposed study. This will be
completed by obtaining the concentration levels of GSH
in the medial prefrontal cortex [21]. The longitudinal
changes of these concentrations will be mapped at three
time periods across the proposed study: between base-
line and 8 weeks to examine for rapid changes; and then
at 52 weeks to assess long-term change. Concentrations
of GSH across the three time periods will be used in our
group-based analyses. The collection of both peripheral
and cortical data will allow a full characterisation of the
effects of NAC on GSH by exploring links between
blood and MRS GSH levels.
Research aims
This project seeks to expand our existing work by
conducting a multi-site randomised placebo-controlled
trial of NAC in the treatment of clozapine-resistant SZ,
with 8, 24 and 52 week assessments. We will target
negative symptoms (primary outcome), quality of life
and cognition (secondary outcomes). An additional
novel aspect of this proposed study is the examination
of both peripheral and cortical GSH concentrations, the
latter in a subset of patients using MRS. This will be the
first study using NAC to target drug resistant clozapine
treated SZ patients specifically; and the first to conduct
a 52-week outcome study of the efficacy of NAC in SZ.
It is hypothesised that NAC will be superior to placebo
in the treatment of negative symptoms in SZ patients
currently taking clozapine. Additional benefits are pre-
dicted in their quality of life and cognitive functioning.
Further analysis of peripheral and cortical GSH concen-
trations is expected to show increases, whereby increases
in cortical GSH will increase cortical functioning.
Methods
Study design and plan
The study is a phase IV, multi-site, 2-arm, 52-week, rando-
mised, double-blind, placebo-controlled trial of 2 g of
NAC per day (taken as two 500 mg capsules twice per day
or matching placebo), in 168 participants diagnosed with
SZ (see Fig. 1 for study outline). In addition to baseline
assessments, follow-ups will take place at 8, 24 and
52 weeks (see Table 1 for a list of study assessments). A
subsample at the Melbourne site will be invited to
undergo a brain scan using MRI (N = 42). Scans will be
performed at baseline, 8 and 52 weeks. The study
protocol was approved by the St Vincent’s Hospital
Human Research Ethics Committee (HREC-A HREC-D
030/16), this committee has jurisdiction over all the
participating sites. An executive steering committee (all
authors) oversees project planning, conduct and ongoing
data collation.
Fig. 1 Study Outline
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Setting
The study will be co-ordinated from the Mental Health
Department of St Vincent’s Hospital, a large metropolitan
teaching hospital in Melbourne, Australia. The study will
be conducted across four Australian sites: Melbourne
(St Vincent’s Mental Health Service), Sydney (Cumberland
Hospital), Adelaide (Northern Adelaide Local Health
Network), and Brisbane (Metro South Addiction and
Mental Health Service).
Participants
Forty-two patients will be recruited from each of the
sites, with a total target of 168 participants aged 18–65
years meeting DSM-5 criteria for SZ. Investigators at
each site will be responsible for recruiting participants
through advertising and engagement with clozapine
clinics associated with their site. As we are interested in
clozapine patients who have residual symptoms, all
potential participants will be screened and assessed for
eligibility. The following inclusion criteria are to be
adhered to: (1) Aged 18–65 years; (2) Confirmed diagnosis
of SZ via clinical interview; (3) Have been on clozapine at
an adequate dose for at least 6 months, ascertained by a
current serum level of >350 mcg/L and with residual
symptoms (see 4.)1; (4) Have a PANSS score of ≥60 or at
least two negative symptom items of >42; (5) Have
the capacity to provide consent to the study; and (6)
Be utilising effective contraception (i.e., oral or barrier
contraception) if female and of childbearing age. In
addition, the following exclusion criteria will be applied:
(1) Participants who are currently taking NAC; (2) Partici-
pants who are allergic to NAC or any component of the
preparation; (3) Participants who are currently prescribed
nitro-glycerine (significant potential interaction with
NAC); (4) Participants who have diabetes mellitus and on
insulin replacement (including exenatide) (moderate inter-
action); (5) Participants taking Aralen (moderate inter-
action); (6) Participants who regularly take >200 mg/day
selenium (moderate interaction); (7) Participants who
regularly take anticoagulants (moderate interaction)
(excluding aspirin and non-steroidal anti-inflammatories);
(8) Change in medication from clozapine to another
antipsychotic; (9) Participants with known primary or
secondary autoimmune disorders; (10) Recent gastrointes-
tinal ulcers; (11) Recent renal stones; and (12) Females
who are pregnant or lactating.
Power was calculated to detect a medium effect size of
d = 0.5 as described in an earlier NAC and SZ paper [5]
and the calculations followed the method described by
Diggle et al. [23]. These calculations assumed one primary
outcome measure (PANSS Negative scores), four assess-
ment points (baseline, 8-weeks, 24-weeks, and 52-weeks
follow-ups), a study-wide Type I error rate (α) of 0.01, a
Type II error rate (β) of 0.10 (power of 0.90), a correlation
of post-treatment scores with baseline measurements (ρ)
of 0.70, employing a two-tailed statistical test. To detect
Table 1 Study Assessments and Timeline
0 week 2, 4 & 6 w 8 weeks 24 weeks 52 weeks
General Demographic questionnaire X X1 X3 X3
Diagnosis MINI X
Symptoms Interview to rate PANSS and CAINS X X X X
Calgary depression scale for schizophrenia
(CDSS) combined with the Montgomery
Asberg Depression Scale (MADRS)
X X X X
Safety Adverse symptoms checklist (SAFTEE) X X2 X X X
ECG X X
Blood test for clozapine monitoring X X X X
QoL Manchester Quality of Life Scale (MANSA) X X X X
Assessment of Quality of Life (AQoL) X X X X
Cognition The Wechsler test of adult reading (WTAR):
Premorbid IQ
X
Wechsler abbreviated scale of IQ (WASI):
Current IQ
X X X X
MATRICS X X X X
Biomarkers Blood sample for biomarkers X X X X
Neuro-imaging3 Magnetic resonance spectroscopy
(MRS)
X X X
1Shortened version to note for changes in work, study, living arrangements
2Telephone safety check
3Only participants who are in the Melbourne arm and provide informed consent for the imaging component will be administered these additional assessments
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the effect size of d = 0.5, 45 participants in each of the
control and intervention groups will be required. Allowing
for up to 46 % attrition (based on a 20 % dropout over the
first 8 weeks and a further 30 % dropout over the ensuing
44 weeks), a total of 168 participants, or 84 in each group
will be recruited. Similar attrition rates are reported in
other treatment trials with treatment resistant SZ. To
accommodate the required number of patients, at least 42
will need to be recruited from each of the four study sites.
For the MRS component, groups of 15–20 are widely
accepted as an appropriate size to permit appropriate
neuroimaging analysis. As noted earlier the anticipated
numbers, including drop out and ineligibility for the MRS
component are 40 at baseline, 36 at 8-weeks and 52-
weeks. Thus, the current study will be adequately powered
for the MRS component.
Consent
The process of consent will be in accordance with the
Declaration of Helsinki. All eligible patients will be fully
informed that they are being asked to participate in a
RCT. The procedures involved in the study, and the
chances of being assigned randomly to one of two
groups will be explained verbally and via an information
sheet approved by the hospital’s Human Research Ethics
Committee. All participants will provide informed
consent by reading the information sheet, asking any
questions they need to and subsequently signing the
consent form in front of an independent witness. Partici-
pants will be made aware of their right to withdraw from
the study at any time without any effects on their clinical
management.
Randomisation and blinding
The study procedure will follow the SPIRIT guideline
[24]. The trial is a randomised, controlled, double-
blinded superiority trial of two parallel patient
groups. Randomisation will be performed independ-
ently of the researchers by an independent re-
searcher and will employ block randomisation (2 × 4)
with a 1:1 allocation to NAC or placebo. Allocation
will be concealed from local investigators, who will
assign a number to the participant that will be
linked to a prescription from the associated phar-
macy. All participants will be dispensed the same
number of capsules each month.
Withdrawal criteria
Participants may be withdrawn from the study for the
following reasons: cessation of clozapine; non-adherence
to medication; emergence of adverse events; pregnancy/
cessation effective contraception; or withdrawal of con-
sent. If a participant is prematurely withdrawn from the
study for any reason after product administration, the
investigator will make every effort to perform these
follow up assessments: review of medications and adverse
events. This information will be recorded in the case
report form (CRF). In all cases, the reason for withdrawal
will be recorded in the CRF.
Treatment of participants
The trial treatments are NAC and placebo. Participants
must take 2 capsules twice per day (total 2 g of NAC) or
matched placebo for 52 weeks. NAC is a GSH precursor.
It is very efficiently bioavailable and is rapidly deacety-
lated by the liver into cysteine. Plasma cysteine levels
can be rapidly increased by NAC supplementation. NAC
rapidly and safely increases plasma cysteine levels,
indirectly replenishing depleted systemic GSH. It is
available over the counter and is approved in Australia
by the Therapeutic Goods Administration (TGA) in
injectable and inhalant forms for treatment of para-
cetamol overdose.
The NAC and placebo capsules will be identical in
colour, size and shape, and will be packaged in identical
bottles. NAC has a mild odour and to cover this differ-
ence between placebo and NAC, a sachet of NAC
powder will be placed in all medication bottles so the
same smell is present for all study capsules. Each of the
treatments will be clearly labelled with a treatment num-
ber by an independent researcher. The trial products will
be stored in accordance with manufacturer’s instructions
which adopt Pharmaceutical Good Manufacturing Prac-
tice. Until dispensed to the participants, the trial prod-
ucts will be stored in a securely locked area, accessible
only to authorised personnel, in accordance with GCP
drug storage requirements.
Participants will be required to take the capsules as
instructed during the 52 weeks of the study. At each
assessment session they will be asked to return all
unused capsules which will be counted for compliance
rate. If less than 50 % of the capsules have been taken at
any assessment point this will be viewed as non-
compliance.
Assessments
The Mini International Neuropsychiatric Interview –
(MINI 6.0) will be used to confirm the diagnosis of
SZ and to screen for other co-morbid conditions. The
MINI 6.0 is a brief, fully structured instrument which
assesses the presence of DSM-5 mood disorders, anx-
iety disorders, substance use disorders, and antisocial
personality disorder. It employs different time frames
for various disorders: current or past. The questions
asked are aimed at specific psychological problems
which require only ‘yes’ or ‘no’ answers. Psychometric
evaluation of the MINI 6.0 shows acceptable test-
retest and inter-rater reliability [25].
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Outcome and process measures
Primary outcome measures
PANSS and CAINS Symptoms
The PANSS [26] and the Clinical Assessment Interview
for Negative Symptoms (CAINS) [27] will be administered
at baseline, 8, 24 and 52 weeks. The PANSS assesses
Global Positive, Negative and General Psychopathology,
and provides a well standardised method of evaluating
and monitoring psychotic symptoms. The CAINS pro-
vides a more detailed examination of negative symptoms
specifically. In the baseline assessment participants will be
screened for the presence of negative symptoms with the
PANSS and CAINS and only included in the study if they
score PANSS >60 total or have at least two negative symp-
tom items of >4.
In addition to these measures, the Calgary Depression
Scale for Schizophrenia (CDSS) [28] combined with the
Montgomery Asberg Depression Scale (MADRS) [29]
will be administered so depression can be accounted for
in the analysis of negative symptoms. The diagnostic
interview and PANSS/CAINS assessment can take up to
90 min to complete. As previously noted if, after the
MINI and PANSS/CAINS interviews are completed the
participant is found not to fulfil the inclusion criteria the
rest of the clinical interview (general measures and other
symptom measures) will not be completed. The primary
outcome measure for this trial will be changes to scores
on the negative subscale of the PANSS and CAINS.
Reductions in severity of negative symptoms in the NAC
group compared with the placebo group will indicate
that NAC is successfully treating these symptoms.
Secondary outcome measures
Quality of life
The Manchester Quality of Life Scale (MANSA) [30] is
a revised and shortened version of the better known
Lancashire Quality of Life Profile. It is a structured self-
report interview completed with a trained interviewer
that contains 16 items to provide objective and subjective
ratings of quality of life in people living with SZ. It will be
completed alongside the Assessment of Quality of Life
(AQoL-4D) [31]. This is a 12-item questionnaire assessing
quality of life across four dimensions: independent living,
relationships, mental health and sense. A secondary
outcome measure for this trial will be changes on these
two measures of QoL. Changes indicating improvement in
the NAC group specifically will indicate the impact of
NAC in the predicted direction.
Cognition
A comprehensive assessment of neurocognition across
multiple domains will be performed. It will include: (1)
The Wechsler Test of Adult Reading, WTAR [32], a
short (1 min) word reading task that provides a measure
of premorbid intelligence; (2) The Weschler abbreviated
scale of IQ (WASI) [33], a 10 min assessment of current
IQ; and (3) The MATRICS battery [34], an eight-domain
cognitive battery that has been constructed to examine
the major cognitive impairments reported in psychosis
and related conditions. It assesses speed of processing,
attention, verbal learning, working memory, visual learn-
ing, reasoning and problem solving, and social cognition.
The MATRICS takes no longer than 80 min to
complete. A scaled score can be calculated for each of
the domains along with an overall general cognition
score. Another secondary outcome measure of this trial
will be cognitive performance. Significant improvements
in cognitive performance in the NAC group over the




Blood samples will be collected. Biomarkers include
thiols (such as GSH, cysteine, cysteinyl-glycine, NAC)
and corresponding disulphides (such as glutathione
disulphide (GSSG) and cystine). This collection for
biomarker analyses will occur at baseline, 8, 24 and
52 weeks, to monitor for peripheral changes.
Magnetic Resonance Spectroscopy (MRS): Cortical
glutathione
A sub-set of participants (N = 42) will be invited to
undergo MRI scans. Scans will be acquired using
Swinburne University’s (Melbourne) Siemens Trio 3
Tesla MRI (Siemens AG, Munich, Germany). Partici-
pants will spend 1 hour in the scanner. An MRS
sequence enables the measurement of levels of metabo-
lites found in the brain. The cerebral metabolites that will
be measured in the current study are creatine (Cre) and
GSH. MRS voxels will be prescribed in the medial
prefrontal cortex (mPFC) and will be 50 × 30 × 30 mm.
The voxel will be positioned using an axial T1-weighted
gradient-echo image. Spectral processing with be per-
formed using LCModel software which permits us to
calculate GSH concentrations (calculated in reference to
total Cre).
Safety
The Adverse Symptom Checklist (known as SAFTEE) is a
21-item scale that rates the presence and severity (0 = not
present to 3 = severe) of common symptoms associated
with psychotropic treatments. As well as being assessed at
baseline, 8, 24 and 52 weeks, a telephone assessment at 2,
4 and 6 weeks will also be completed using this assess-
ment. Clozapine levels will be measured at baseline and 8,
24 and 52 weeks to ensure adherence and to ascertain any
pharmacokinetic interactions with NAC (we do not expect
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any such effects as the kinetics of the two agents do not
suggest interaction). As well as clozapine levels, hepatic
and renal function, full blood count, other metabolic
information and electrocardiogram (ECG) will be per-
formed as part of routine clozapine monitoring will be
maintained according to local requirements.
Data management
Data will first be entered into a handwritten patient file
and later entered into a computerised database designed
for this trial. Double data entry will be completed for
10 % of all study files.
Statistical analyses
Data will be analysed using R 3.1.2 (R Foundation for
Statistical Computing, Vienna, Austria and SPSS where
relevant). Intention-to-treat analyses will be employed to
prevent over-estimation of efficacy. Categorical variables
will be analysed using chi-squared tests (or Fisher’s exact
test for small samples). A mixed-effects model, repeated
measures (MMRM) approach will be used to examine
the longitudinal profile of all continuous variables at
weeks 8, 24, and 52 post-baseline. For all MMRM
analyses, baseline scores will be used as covariates and
the models will include pre-specified fixed effects of
treatment, site, and time, and treatment-by-time and
treatment-by-site interactions.
The MMRM modelling for the primary outcome
measure – PANSS negative scores and CAINS scores –
will also include baseline PANSS Positive, Negative, and
General Psychopathology scores, as covariates. The sec-
ondary outcomes consist of MANSA, AQoL and MCCB
global score, while the process outcomes include GSH
concentrations peripherally and cortically, respectively.
Secondary analyses using Analysis of Covariance will be
conducted to compare change scores during treatment
and follow-up phases for all primary, secondary, and
process outcomes using treatment group as a main effect
with the baseline score as a covariate. Site will not be
included in the analysis for the MRS data, but will be for
the peripheral data. Correlational analyses will also be
performed to examine for relationships between outcome
variables (i.e., treatment response with cognition and GSH
levels, peripherally and cortically).
Although the attrition rate is not expected to vary by
treatment condition, we will attempt to identify key pre-
dictors of attrition status (i.e., demographic and baseline
clinical characteristics) and test for differences between
conditions. Assuming the data are missing at random,
several procedures offer effective approaches that may
deal with attrition, statistically. Maximum likelihood
models, with time as a random variable, allow the use of
all available data from all assessments, reducing bias and
increasing power [35]. There are three other accepted
approaches to analyses with missing data: (a) multiple
imputation procedures that utilise the expectation-
maximization (EM) algorithm with bootstrap estimates
of standard errors; (b) raw maximum-likelihood analysis;
or (c) multiple-group structural equation or latent
growth modelling [23]. For manifest variable models,
these methods produce virtually identical results and will
be used to address attrition. In general, the application
of these missing data procedures can provide unbiased
estimates, even in the face of substantial attrition.
Data monitoring
A Data Safety Monitoring Board (DSMB) will oversee
the conduct of the current trial. This board includes four
experts external to the trial team.
Discussion
SZ is one of the most disabling chronic diseases for
people aged 18–45 years, and impacts multiple domains
of functioning as well as increasing mortality risks.
Current treatments remain suboptimal for many patients,
with residual negative and cognitive symptoms being
particularly disabling. Improvements and advances in the
intervention options for treatment-resistant psychosis are
in great demand. Whilst clozapine has profound benefits
for some individuals who do not respond to other anti-
psychotics, it is not as effective for many others. This large
scale clinical trial will investigate the efficacy of NAC as a
possible adjunctive medication to clozapine. In addition,
this trial will run for 52 weeks providing the longest follow
up examination of the impact of NAC on SZ to date.
This trial, if successful, will establish a cheap, safe
and easy-to-use agent (NAC) as a ‘go to’ adjunct in
patients only partly responsive to clozapine. This
work will provide crucial information regarding the
clinical value of this treatment approach. Given the
personal and societal cost of treatment resistant psychosis,
the research will therefore have great importance for this
mental health condition. In addition, we will be able to
assess in detail the effects of this agent on cognitive func-
tioning as well as investigating in some detail the glutathi-
one hypothesis of SZ, by examining peripheral and cortical
markers of glutamatergic activity.
Trial status
Patient recruitment was about to commence at the time
of manuscript submission. Data collection will continue
until at least June 2019.
Australian and New Zealand Clinical Trials Registration
Number (TRN) ACTRN12615001273572 https://www.anzc-
tr.org.au/Trial/Registration/TrialReview.aspx?id=369601.
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Endnotes
1Treatment resistance will be defined using the criteria
of Kane et al. [22], viz: at least three periods of treatment
in the preceding 5 years with antipsychotic drugs from
different chemical classes without significant symptomatic
relief: in Australia, these criteria are obligatory in any
event for commencement of clozapine.
2As we are interested in clozapine patients who have
residual symptoms, all potential participants will be
screened and assessed for eligibility according to these
criteria.
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